m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00213)
Target Name Cyclin-dependent kinase inhibitor 1 (CDKN1A)
Synonyms
CDK-interacting protein 1; Melanoma differentiation-associated protein 6; MDA-6; p21; CAP20; CDKN1; CIP1; MDA6; PIC1; SDI1; WAF1
    Click to Show/Hide
Gene Name CDKN1A
Chromosomal Location 6p21.2
Family CDI family
Function
May be involved in p53/TP53 mediated inhibition of cellular proliferation in response to DNA damage. Binds to and inhibits cyclin-dependent kinase activity, preventing phosphorylation of critical cyclin-dependent kinase substrates and blocking cell cycle progression. Functions in the nuclear localization and assembly of cyclin D-CDK4 complex and promotes its kinase activity towards RB1. At higher stoichiometric ratios, inhibits the kinase activity of the cyclin D-CDK4 complex. Inhibits DNA synthesis by DNA polymerase delta by competing with POLD3 for PCNA binding. Plays an important role in controlling cell cycle progression and DNA damage-induced G2 arrest.
    Click to Show/Hide
Gene ID 1026
Uniprot ID
CDN1A_HUMAN
HGNC ID
HGNC:1784
Ensembl Gene ID
ENSG00000124762
KEGG ID
hsa:1026
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
CDKN1A can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Methyltransferase-like 3 (METTL3) [WRITER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by METTL3
Cell Line LX2 cell line Homo sapiens
Treatment: shMETTL3 LX2 cells
Control: shLuc LX2 cells
 GSE207909
Regulation
logFC: 7.88E-01
p-value: 3.07E-21
More Results Click to View More RNA-seq Results
Representative RIP-seq result supporting the interaction between CDKN1A and the regulator
Cell Line MDA-MB-231 Homo sapiens
Regulation logFC: 9.39E+00 GSE60213
In total 3 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary METTL3 and METTL14 play an oncogenic role in acute myeloid leukemia(AML) by targeting mdm2/p53 signal pathway. The knockdown of METTL3 and METTL14 in K562 cell line leads to several changes in the expression of p53 signal pathway, including the upregulation of p53, cyclin dependent kinase inhibitor 1A (CDKN1A/Cyclin-dependent kinase inhibitor 1 (CDKN1A)), and downregulation of mdm2.
Target Regulation Up regulation
Responsed Disease Acute myeloid leukaemia ICD-11: 2A60
 Disease Info 
Pathway Response p53 signaling pathway hsa04115
Cell cycle hsa04110
Cell Process Cell apoptosis
Cells in G4/M phase decreased
In-vitro Model THP-1 Childhood acute monocytic leukemia Homo sapiens CVCL_0006
NB4 Acute promyelocytic leukemia Homo sapiens CVCL_0005
MV4-11 Childhood acute monocytic leukemia Homo sapiens CVCL_0064
MOLT-4 Adult T acute lymphoblastic leukemia Homo sapiens CVCL_0013
Kasumi-1 Myeloid leukemia with maturation Homo sapiens CVCL_0589
K-562 Chronic myelogenous leukemia Homo sapiens CVCL_0004
HL-60 Adult acute myeloid leukemia Homo sapiens CVCL_0002
HEL Erythroleukemia Homo sapiens CVCL_0001
CCRF-CEM C7 T acute lymphoblastic leukemia Homo sapiens CVCL_6825
HEK293T Normal Homo sapiens CVCL_0063
Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene [2]
Response Summary METTL3 is able to promote breast cancer cell proliferation by regulating the Cyclin-dependent kinase inhibitor 1 (CDKN1A) expression by an m6A-dependent manner. Metformin can take p21 as the main target to inhibit such effect.
Target Regulation Down regulation
Responsed Disease Breast cancer ICD-11: 2C60
 Disease Info 
In-vitro Model ZR-75-1 Invasive breast carcinoma Homo sapiens CVCL_0588
SUM1315MO2 Invasive breast carcinoma of no special type Homo sapiens CVCL_5589
MDA-MB-231 Breast adenocarcinoma Homo sapiens CVCL_0062
MCF-7 Invasive breast carcinoma Homo sapiens CVCL_0031
MCF-10A Normal Homo sapiens CVCL_0598
HBL-100 Normal Homo sapiens CVCL_4362
BT-474 Invasive breast carcinoma Homo sapiens CVCL_0179
In-vivo Model About 1 × 107 stable METTL3 overexpression and negative control SUM-1315 cells were injected subcutaneously into the axilla of the female BALB/C nude mice (4-6 weeks old, 18-20 g, 10 mice/group). One week after injection, the two groups, METTL3 OE and NC, were then randomly allocated into the control group and experimental group (5 mice/group), which were treated with PBS or metformin (250 mg/kg/dose, respectively). PBS or metformin was administered every 2 days via intraperitoneal injection.
Experiment 3 Reporting the m6A Methylation Regulator of This Target Gene [3]
Response Summary METTL3 modulates the cell cycle of Esophageal squamous cell carcinoma(ESCC) cells through a Cyclin-dependent kinase inhibitor 1 (CDKN1A)-dependent pattern. METTL3-guided m6A modification contributes to the progression of ESCC via the p21-axis.
Target Regulation Down regulation
Responsed Disease Esophageal squamous cell carcinoma ICD-11: 2B70.1
 Disease Info 
Pathway Response Cell cycle hsa04110
Cell Process Arrest cell cycle at G2/M phase
In-vitro Model TE-1 Esophageal squamous cell carcinoma Homo sapiens CVCL_1759
KYSE-150 Esophageal squamous cell carcinoma Homo sapiens CVCL_1348
In-vivo Model Totally 5 × 106 ESCC cells after treatment were administered to randomized animals by the subcutaneous route (right flank) in 200 uL DMEM. Tumor measurement was performed every other day. At study end (at least 3 weeks), the animals underwent euthanasia, and the tumors were extracted for histology.
Fat mass and obesity-associated protein (FTO) [ERASER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by FTO
Cell Line 253J cell line Homo sapiens
Treatment: siFTO 253J cells
Control: 253J cells
 GSE150239
Regulation
logFC: 9.72E-01
p-value: 1.24E-24
More Results Click to View More RNA-seq Results
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [4]
Response Summary The elevated FTO in esophageal squamous cell carcinoma decreased m6A methylation of LINC00022 transcript, leading to the inhibition of LINC00022 decay via the m6A reader YTHDF2. LINC00022 directly binds to Cyclin-dependent kinase inhibitor 1 (CDKN1A) protein and promotes its ubiquitination-mediated degradation, thereby facilitating cell-cycle progression and proliferation.
Responsed Disease Esophageal squamous cell carcinoma ICD-11: 2B70.1
 Disease Info 
Pathway Response Cell cycle hsa04110
Ubiquitin mediated proteolysis hsa04120
Cell Process Ubiquitination degradation
Cell apoptosis
Decreased G0/G1 phase
In-vitro Model HET-1A Normal Homo sapiens CVCL_3702
KYSE-150 Esophageal squamous cell carcinoma Homo sapiens CVCL_1348
KYSE-450 Esophageal squamous cell carcinoma Homo sapiens CVCL_1353
KYSE-70 Esophageal squamous cell carcinoma Homo sapiens CVCL_1356
TE-1 Esophageal squamous cell carcinoma Homo sapiens CVCL_1759
In-vivo Model The number of cells inoculated in each mouse was 4 × 106, 1 × 106, 2 × 106 and 1 × 106, respectively.
Methyltransferase-like 14 (METTL14) [WRITER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by METTL14
Cell Line Neural progenitor cell line Mus musculus
Treatment: METTL14 knockout NPCs
Control: Wild type NPCs
 GSE158985
Regulation
logFC: -9.21E-01
p-value: 1.04E-03
More Results Click to View More RNA-seq Results
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary METTL3 and METTL14 play an oncogenic role in acute myeloid leukemia(AML) by targeting mdm2/p53 signal pathway. The knockdown of METTL3 and METTL14 in K562 cell line leads to several changes in the expression of p53 signal pathway, including the upregulation of p53, cyclin dependent kinase inhibitor 1A (CDKN1A/Cyclin-dependent kinase inhibitor 1 (CDKN1A)), and downregulation of mdm2.
Target Regulation Up regulation
Responsed Disease Acute myeloid leukaemia ICD-11: 2A60
 Disease Info 
Pathway Response p53 signaling pathway hsa04115
Cell cycle hsa04110
Cell Process Cell apoptosis
Cells in G7/M phase decreased
In-vitro Model THP-1 Childhood acute monocytic leukemia Homo sapiens CVCL_0006
NB4 Acute promyelocytic leukemia Homo sapiens CVCL_0005
MV4-11 Childhood acute monocytic leukemia Homo sapiens CVCL_0064
MOLT-4 Adult T acute lymphoblastic leukemia Homo sapiens CVCL_0013
Kasumi-1 Myeloid leukemia with maturation Homo sapiens CVCL_0589
K-562 Chronic myelogenous leukemia Homo sapiens CVCL_0004
HL-60 Adult acute myeloid leukemia Homo sapiens CVCL_0002
HEL Erythroleukemia Homo sapiens CVCL_0001
CCRF-CEM C7 T acute lymphoblastic leukemia Homo sapiens CVCL_6825
HEK293T Normal Homo sapiens CVCL_0063
RNA demethylase ALKBH5 (ALKBH5) [ERASER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by ALKBH5
Cell Line CAG cell line Homo sapiens
Treatment: shALKBH5 CAG cells
Control: shNC CAG cells
 GSE180214
Regulation
logFC: -1.90E+00
p-value: 1.35E-05
More Results Click to View More RNA-seq Results
In total 2 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [5]
Response Summary The expression of Cyclin-dependent kinase inhibitor 1 (CDKN1A) or TIMP3 was increased by ALKBH5 knockdown. In conclusions, the ALKBH5-IGF2BPs axis promotes cell proliferation and tumorigenicity, which in turn causes the unfavorable prognosis of NSCLC.
Target Regulation Down regulation
Responsed Disease Non-small-cell lung carcinoma ICD-11: 2C25.Y
 Disease Info 
Pathway Response Cell cycle hsa04110
Cell Process Arrest cell cycle at G1 phase
In-vitro Model NCI-H1299 Lung large cell carcinoma Homo sapiens CVCL_0060
NCI-H460 Lung large cell carcinoma Homo sapiens CVCL_0459
NCI-H2087 Lung adenocarcinoma Homo sapiens CVCL_1524
A-549 Lung adenocarcinoma Homo sapiens CVCL_0023
ABC-1 Lung adenocarcinoma Homo sapiens CVCL_1066
NCI-H358 Minimally invasive lung adenocarcinoma Homo sapiens CVCL_1559
BEAS-2B Normal Homo sapiens CVCL_0168
HEK293 Normal Homo sapiens CVCL_0045
PC-3 [Human lung carcinoma] Lung adenocarcinoma Homo sapiens CVCL_S982
PC-9 Lung adenocarcinoma Homo sapiens CVCL_B260
RERF-LC-MS Lung adenocarcinoma Homo sapiens CVCL_1655
HLC-1 Lung adenocarcinoma Homo sapiens CVCL_5529
LC-2/ad Lung adenocarcinoma Homo sapiens CVCL_1373
Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene [6]
Response Summary Expression of CDKN1A (p21) was significantly up-regulated in ALKBH5-depleted cells, and m6 A modification and stability of Cyclin-dependent kinase inhibitor 1 (CDKN1A) mRNA were increased by ALKBH5 knockdown. Identify ALKBH5 as the first m6 A demethylase that accelerates cell cycle progression and promotes cell proliferation of ESCC cells, which is associated with poor prognosis of esophageal squamous cell carcinoma patients.
Target Regulation Down regulation
Responsed Disease Esophageal squamous cell carcinoma ICD-11: 2B70.1
 Disease Info 
Pathway Response Cell cycle hsa04110
Cell Process Cell cycle
Cell apoptosis
In-vitro Model OE21 Esophageal squamous cell carcinoma Homo sapiens CVCL_2661
TE-1 Esophageal squamous cell carcinoma Homo sapiens CVCL_1759
TE-5 Esophageal squamous cell carcinoma Homo sapiens CVCL_1764
TE-9 Esophageal squamous cell carcinoma Homo sapiens CVCL_1767
In-vivo Model The OE21 cells were stably transfected with sh-ALKBH5 (#1), sh-ALKBH5 (#2) or sh-scramble as negative control and injected (2 × 106 cells/mouse in 100 uL volume) subcutaneously into the back of male athymic BALB/c nude mice (6 weeks old, Japan SLC).
YTH domain-containing protein 2 (YTHDC2) [READER]
 Regulator Info 
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [7]
Response Summary Knockdown of YTHDC2 substantially promoted the proliferation rate of esophageal squamous cell carcinoma cells by affecting several cancer-related signaling pathways.
Target Regulation Up regulation
Responsed Disease Esophageal squamous cell carcinoma ICD-11: 2B70.1
 Disease Info 
Pathway Response p53 signaling pathway hsa04115
NF-kappa B signaling pathway hsa04064
JAK-STAT signaling pathway hsa04630
Cell Process Genetic variants
In-vitro Model KYSE-150 Esophageal squamous cell carcinoma Homo sapiens CVCL_1348
KYSE-30 Esophageal squamous cell carcinoma Homo sapiens CVCL_1351
Acute myeloid leukaemia [ICD-11: 2A60]
 Disease Info 
In total 2 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary METTL3 and METTL14 play an oncogenic role in acute myeloid leukemia(AML) by targeting mdm2/p53 signal pathway. The knockdown of METTL3 and METTL14 in K562 cell line leads to several changes in the expression of p53 signal pathway, including the upregulation of p53, cyclin dependent kinase inhibitor 1A (CDKN1A/Cyclin-dependent kinase inhibitor 1 (CDKN1A)), and downregulation of mdm2.
Responsed Disease Acute myeloid leukaemia [ICD-11: 2A60]
Target Regulator Methyltransferase-like 14 (METTL14) WRITER
 Regulator Info 
Target Regulation Up regulation
Pathway Response p53 signaling pathway hsa04115
Cell cycle hsa04110
Cell Process Cell apoptosis
Cells in G7/M phase decreased
In-vitro Model THP-1 Childhood acute monocytic leukemia Homo sapiens CVCL_0006
NB4 Acute promyelocytic leukemia Homo sapiens CVCL_0005
MV4-11 Childhood acute monocytic leukemia Homo sapiens CVCL_0064
MOLT-4 Adult T acute lymphoblastic leukemia Homo sapiens CVCL_0013
Kasumi-1 Myeloid leukemia with maturation Homo sapiens CVCL_0589
K-562 Chronic myelogenous leukemia Homo sapiens CVCL_0004
HL-60 Adult acute myeloid leukemia Homo sapiens CVCL_0002
HEL Erythroleukemia Homo sapiens CVCL_0001
CCRF-CEM C7 T acute lymphoblastic leukemia Homo sapiens CVCL_6825
HEK293T Normal Homo sapiens CVCL_0063
Experiment 2 Reporting the m6A-centered Disease Response [1]
Response Summary METTL3 and METTL14 play an oncogenic role in acute myeloid leukemia(AML) by targeting mdm2/p53 signal pathway. The knockdown of METTL3 and METTL14 in K562 cell line leads to several changes in the expression of p53 signal pathway, including the upregulation of p53, cyclin dependent kinase inhibitor 1A (CDKN1A/Cyclin-dependent kinase inhibitor 1 (CDKN1A)), and downregulation of mdm2.
Responsed Disease Acute myeloid leukaemia [ICD-11: 2A60]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Up regulation
Pathway Response p53 signaling pathway hsa04115
Cell cycle hsa04110
Cell Process Cell apoptosis
Cells in G4/M phase decreased
In-vitro Model THP-1 Childhood acute monocytic leukemia Homo sapiens CVCL_0006
NB4 Acute promyelocytic leukemia Homo sapiens CVCL_0005
MV4-11 Childhood acute monocytic leukemia Homo sapiens CVCL_0064
MOLT-4 Adult T acute lymphoblastic leukemia Homo sapiens CVCL_0013
Kasumi-1 Myeloid leukemia with maturation Homo sapiens CVCL_0589
K-562 Chronic myelogenous leukemia Homo sapiens CVCL_0004
HL-60 Adult acute myeloid leukemia Homo sapiens CVCL_0002
HEL Erythroleukemia Homo sapiens CVCL_0001
CCRF-CEM C7 T acute lymphoblastic leukemia Homo sapiens CVCL_6825
HEK293T Normal Homo sapiens CVCL_0063
Lung cancer [ICD-11: 2C25]
 Disease Info 
In total 2 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response []
Response Summary In lung squamous cell carcinoma, seven m6A-related autophagy genes were screened to construct a prognostic model: CASP4, Cyclin-dependent kinase inhibitor 1 (CDKN1A), DLC1, ITGB1, PINK1, TP63, and EIF4EBP1.
Responsed Disease Lung squamous cell carcinoma [ICD-11: 2C25.2]
Pathway Response Autophagy hsa04140
Cell Process Cell proliferation and metastasis
Cell autophagy
Experiment 2 Reporting the m6A-centered Disease Response [5]
Response Summary The expression of Cyclin-dependent kinase inhibitor 1 (CDKN1A) or TIMP3 was increased by ALKBH5 knockdown. In conclusions, the ALKBH5-IGF2BPs axis promotes cell proliferation and tumorigenicity, which in turn causes the unfavorable prognosis of NSCLC.
Responsed Disease Non-small-cell lung carcinoma [ICD-11: 2C25.Y]
Target Regulator RNA demethylase ALKBH5 (ALKBH5) ERASER
 Regulator Info 
Target Regulation Down regulation
Pathway Response Cell cycle hsa04110
Cell Process Arrest cell cycle at G1 phase
In-vitro Model NCI-H1299 Lung large cell carcinoma Homo sapiens CVCL_0060
NCI-H460 Lung large cell carcinoma Homo sapiens CVCL_0459
NCI-H2087 Lung adenocarcinoma Homo sapiens CVCL_1524
A-549 Lung adenocarcinoma Homo sapiens CVCL_0023
ABC-1 Lung adenocarcinoma Homo sapiens CVCL_1066
NCI-H358 Minimally invasive lung adenocarcinoma Homo sapiens CVCL_1559
BEAS-2B Normal Homo sapiens CVCL_0168
HEK293 Normal Homo sapiens CVCL_0045
PC-3 [Human lung carcinoma] Lung adenocarcinoma Homo sapiens CVCL_S982
PC-9 Lung adenocarcinoma Homo sapiens CVCL_B260
RERF-LC-MS Lung adenocarcinoma Homo sapiens CVCL_1655
HLC-1 Lung adenocarcinoma Homo sapiens CVCL_5529
LC-2/ad Lung adenocarcinoma Homo sapiens CVCL_1373
Breast cancer [ICD-11: 2C60]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [2]
Response Summary METTL3 is able to promote breast cancer cell proliferation by regulating the Cyclin-dependent kinase inhibitor 1 (CDKN1A) expression by an m6A-dependent manner. Metformin can take p21 as the main target to inhibit such effect.
Responsed Disease Breast cancer [ICD-11: 2C60]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Down regulation
In-vitro Model ZR-75-1 Invasive breast carcinoma Homo sapiens CVCL_0588
SUM1315MO2 Invasive breast carcinoma of no special type Homo sapiens CVCL_5589
MDA-MB-231 Breast adenocarcinoma Homo sapiens CVCL_0062
MCF-7 Invasive breast carcinoma Homo sapiens CVCL_0031
MCF-10A Normal Homo sapiens CVCL_0598
HBL-100 Normal Homo sapiens CVCL_4362
BT-474 Invasive breast carcinoma Homo sapiens CVCL_0179
In-vivo Model About 1 × 107 stable METTL3 overexpression and negative control SUM-1315 cells were injected subcutaneously into the axilla of the female BALB/C nude mice (4-6 weeks old, 18-20 g, 10 mice/group). One week after injection, the two groups, METTL3 OE and NC, were then randomly allocated into the control group and experimental group (5 mice/group), which were treated with PBS or metformin (250 mg/kg/dose, respectively). PBS or metformin was administered every 2 days via intraperitoneal injection.
Oral cavity/oesophagus/stomach in situ carcinoma [ICD-11: 2E60]
 Disease Info 
In total 4 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [4]
Response Summary The elevated FTO in esophageal squamous cell carcinoma decreased m6A methylation of LINC00022 transcript, leading to the inhibition of LINC00022 decay via the m6A reader YTHDF2. LINC00022 directly binds to Cyclin-dependent kinase inhibitor 1 (CDKN1A) protein and promotes its ubiquitination-mediated degradation, thereby facilitating cell-cycle progression and proliferation.
Responsed Disease Esophageal squamous cell carcinoma [ICD-11: 2B70.1]
Target Regulator Fat mass and obesity-associated protein (FTO) ERASER
 Regulator Info 
Pathway Response Cell cycle hsa04110
Ubiquitin mediated proteolysis hsa04120
Cell Process Ubiquitination degradation
Cell apoptosis
Decreased G0/G1 phase
In-vitro Model HET-1A Normal Homo sapiens CVCL_3702
KYSE-150 Esophageal squamous cell carcinoma Homo sapiens CVCL_1348
KYSE-450 Esophageal squamous cell carcinoma Homo sapiens CVCL_1353
KYSE-70 Esophageal squamous cell carcinoma Homo sapiens CVCL_1356
TE-1 Esophageal squamous cell carcinoma Homo sapiens CVCL_1759
In-vivo Model The number of cells inoculated in each mouse was 4 × 106, 1 × 106, 2 × 106 and 1 × 106, respectively.
Experiment 2 Reporting the m6A-centered Disease Response [3]
Response Summary METTL3 modulates the cell cycle of Esophageal squamous cell carcinoma(ESCC) cells through a Cyclin-dependent kinase inhibitor 1 (CDKN1A)-dependent pattern. METTL3-guided m6A modification contributes to the progression of ESCC via the p21-axis.
Responsed Disease Esophageal squamous cell carcinoma [ICD-11: 2B70.1]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Down regulation
Pathway Response Cell cycle hsa04110
Cell Process Arrest cell cycle at G2/M phase
In-vitro Model TE-1 Esophageal squamous cell carcinoma Homo sapiens CVCL_1759
KYSE-150 Esophageal squamous cell carcinoma Homo sapiens CVCL_1348
In-vivo Model Totally 5 × 106 ESCC cells after treatment were administered to randomized animals by the subcutaneous route (right flank) in 200 uL DMEM. Tumor measurement was performed every other day. At study end (at least 3 weeks), the animals underwent euthanasia, and the tumors were extracted for histology.
Experiment 3 Reporting the m6A-centered Disease Response [6]
Response Summary Expression of CDKN1A (p21) was significantly up-regulated in ALKBH5-depleted cells, and m6 A modification and stability of Cyclin-dependent kinase inhibitor 1 (CDKN1A) mRNA were increased by ALKBH5 knockdown. Identify ALKBH5 as the first m6 A demethylase that accelerates cell cycle progression and promotes cell proliferation of ESCC cells, which is associated with poor prognosis of esophageal squamous cell carcinoma patients.
Responsed Disease Esophageal squamous cell carcinoma [ICD-11: 2B70.1]
Target Regulator RNA demethylase ALKBH5 (ALKBH5) ERASER
 Regulator Info 
Target Regulation Down regulation
Pathway Response Cell cycle hsa04110
Cell Process Cell cycle
Cell apoptosis
In-vitro Model OE21 Esophageal squamous cell carcinoma Homo sapiens CVCL_2661
TE-1 Esophageal squamous cell carcinoma Homo sapiens CVCL_1759
TE-5 Esophageal squamous cell carcinoma Homo sapiens CVCL_1764
TE-9 Esophageal squamous cell carcinoma Homo sapiens CVCL_1767
In-vivo Model The OE21 cells were stably transfected with sh-ALKBH5 (#1), sh-ALKBH5 (#2) or sh-scramble as negative control and injected (2 × 106 cells/mouse in 100 uL volume) subcutaneously into the back of male athymic BALB/c nude mice (6 weeks old, Japan SLC).
Experiment 4 Reporting the m6A-centered Disease Response [7]
Response Summary Knockdown of YTHDC2 substantially promoted the proliferation rate of esophageal squamous cell carcinoma cells by affecting several cancer-related signaling pathways.
Responsed Disease Esophageal squamous cell carcinoma [ICD-11: 2B70.1]
Target Regulator YTH domain-containing protein 2 (YTHDC2) READER
 Regulator Info 
Target Regulation Up regulation
Pathway Response p53 signaling pathway hsa04115
NF-kappa B signaling pathway hsa04064
JAK-STAT signaling pathway hsa04630
Cell Process Genetic variants
In-vitro Model KYSE-150 Esophageal squamous cell carcinoma Homo sapiens CVCL_1348
KYSE-30 Esophageal squamous cell carcinoma Homo sapiens CVCL_1351
References
Ref 1 The m(6)A RNA methyltransferase METTL3/METTL14 promotes leukemogenesis through the mdm2/p53 pathway in acute myeloid leukemia. J Cancer. 2022 Jan 4;13(3):1019-1030. doi: 10.7150/jca.60381. eCollection 2022.
Ref 2 Metformin exhibits antiproliferation activity in breast cancer via miR-483-3p/METTL3/m(6)A/p21 pathway. Oncogenesis. 2021 Jan 5;10(1):7. doi: 10.1038/s41389-020-00290-y.
Ref 3 The M6A methyltransferase METTL3 regulates proliferation in esophageal squamous cell carcinoma. Biochem Biophys Res Commun. 2021 Nov 26;580:48-55. doi: 10.1016/j.bbrc.2021.05.048. Epub 2021 Oct 5.
Ref 4 RNA m6A demethylase FTO-mediated epigenetic up-regulation of LINC00022 promotes tumorigenesis in esophageal squamous cell carcinoma. J Exp Clin Cancer Res. 2021 Sep 20;40(1):294. doi: 10.1186/s13046-021-02096-1.
Ref 5 m(6)A demethylase ALKBH5 promotes tumor cell proliferation by destabilizing IGF2BPs target genes and worsens the prognosis of patients with non-small-cell lung cancer. Cancer Gene Ther. 2022 Mar 22. doi: 10.1038/s41417-022-00451-8. Online ahead of print.
Ref 6 m(6) A demethylase ALKBH5 promotes proliferation of esophageal squamous cell carcinoma associated with poor prognosis. Genes Cells. 2020 Aug;25(8):547-561. doi: 10.1111/gtc.12792. Epub 2020 Jul 1.
Ref 7 Genetic variants in m6A modification genes are associated with esophageal squamous-cell carcinoma in the Chinese population. Carcinogenesis. 2020 Jul 10;41(6):761-768. doi: 10.1093/carcin/bgaa012.